Evidence map›Paper›PMID 17553165›Full record

ArticleMolecular cancer2007

Identification of novel androgen receptor target genes in prostate cancer.

Unnati Jariwala, Jennifer Prescott, Li Jia, Artem Barski, Steve Pregizer, Jon P Cogan, Armin Arasheben, Wayne D Tilley, Howard I Scher, William L Gerald and 3 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Molecular cancer, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 109 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Cellular Signaling of Amino Acid Metabolism in Prostate Cancer.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Article
  7. Novel Fragment Inhibitors of PYCR1 from Docking-Guided X-ray Crystallography.Journal of chemical information and modeling · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Unnati JariwalaDepartment of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, USA. jariwala@usc.edu
Jennifer Prescott
Li Jia
Artem Barski
Steve Pregizer
Jon P Cogan
Armin Arasheben
Wayne D Tilley
Howard I Scher
William L Gerald
Grant Buchanan
Gerhard A Coetzee
Baruch Frenkel
University of Southern California · USMemorial Sloan Kettering Cancer Center · USHanson Institute · AUUniversity of Adelaide · AU

Funding

SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0M
Sex Steroids and Runx Signaling in BoneR01DK071122 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FRENKEL, BARUCH · 2005 to 2013
$2.5M
Training in Genetic, Molecular and Cellular BiologyT32GM067587 · NIGMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI STALLCUP, MICHAEL R · 2003 to 2012
$1.8M
AR and RUNX2 target genes in prostate cancerR01CA109147 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI COETZEE, GERHARD A · 2006 to 2010
$1.3M
Runx Proteins and Sex Steroid Signaling in BoneR56DK071122 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FRENKEL, BARUCH, SCHONES, DUSTIN EDWARD · 2009 to 2017
$603k
EXTRAMURAL RESEARCH FACILITIES CONTRUCTION PROJECTC06CA062528 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KEDES, LAURENCE H · 1993 to 1994
–
RESEARCH FACILITIES IMPROVEMENT PROGRAM AND REMODELINGC06RR014514 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KEDES, LAURENCE H · 1999 to 1999
–
EXTRAMURAL RESEARCH FACILITIES CONSTRUCTIONC06RR010600 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KEDES, LAURENCE H · 1994 to 1994
–
NCI NIH HHS C06 CA062528NCI NIH HHS CA109147NCI NIH HHS CA62528-01NCI NIH HHS P50 CA092629NCI NIH HHS P50 CA92629NCI NIH HHS R01 CA109147NCRR NIH HHS C06 RR014514NCRR NIH HHS RR10600-01NCRR NIH HHS RR14514-01NIDDK NIH HHS DK071122NIDDK NIH HHS R01 DK071122NIDDK NIH HHS R56 DK071122NIGMS NIH HHS T 32 GM067587
6 · The paper itself

Abstract

backgroundThe androgen receptor (AR) plays critical roles in both androgen-dependent and castrate-resistant prostate cancer (PCa). However, little is known about AR target genes that mediate the receptor's roles in disease progression.

resultsUsing Chromatin Immunoprecipitation (ChIP) Display, we discovered 19 novel loci occupied by the AR in castrate resistant C4-2B PCa cells. Only four of the 19 AR-occupied regions were within 10-kb 5'-flanking regulatory sequences. Three were located up to 4-kb 3' of the nearest gene, eight were intragenic and four were in gene deserts. Whereas the AR occupied the same loci in C4-2B (castrate resistant) and LNCaP (androgen-dependent) PCa cells, differences between the two cell lines were observed in the response of nearby genes to androgens. Among the genes strongly stimulated by DHT in C4-2B cells--D-dopachrome tautomerase (DDT), Protein kinase C delta (PRKCD), Glutathione S- transferase theta 2 (GSTT2), Transient receptor potential cation channel subfamily V member 3 (TRPV3), and Pyrroline-5-carboxylate reductase 1 (PYCR1)--most were less strongly or hardly stimulated in LNCaP cells. Another AR target gene, ornithine aminotransferase (OAT), was AR-stimulated in a ligand-independent manner, since it was repressed by AR siRNA knockdown, but not stimulated by DHT. We also present evidence for in vivo AR-mediated regulation of several genes identified by ChIP Display. For example, PRKCD and PYCR1, which may contribute to PCa cell growth and survival, are expressed in PCa biopsies from primary tumors before and after ablation and in metastatic lesions in a manner consistent with AR-mediated stimulation.

conclusionAR genomic occupancy is similar between LNCaP and C4-2B cells and is not biased towards 5' gene flanking sequences. The AR transcriptionally regulates less than half the genes nearby AR-occupied regions, usually but not always, in a ligand-dependent manner. Most are stimulated and a few are repressed. In general, response is stronger in C4-2B compared to LNCaP cells. Some of the genes near AR-occupied regions appear to be regulated by the AR in vivo as evidenced by their expression levels in prostate cancer tumors of various stages. Several AR target genes discovered in the present study, for example PRKCD and PYCR1, may open avenues in PCa research and aid the development of new approaches for disease management.

Indexed as

AndrogensGene Expression Regulation, NeoplasticAdenocarcinomaBinding SitesCell Adhesion MoleculesCell Line, TumorChromosomes, Humandelta-1-Pyrroline-5-Carboxylate ReductaseDihydrotestosteroneExtracellular Matrix ProteinsGene Expression ProfilingGlutathione TransferaseHumansIntracellular Signaling Peptides and ProteinsMaleMucin-6AndrogensCell Adhesion MoleculesCRELD2 protein, humandelta-1-Pyrroline-5-Carboxylate ReductaseDihydrotestosteroneExtracellular Matrix ProteinsGlutathione TransferaseGSTT2 protein, humanIntracellular Signaling Peptides and ProteinsMRFAP1 protein, humanMUC6 protein, humanMucin-6MucinsNeoplasm ProteinsNuclear ProteinsOrnithine-Oxo-Acid TransaminasePRKCD protein, humanProtein Kinase C-deltaPyrroline Carboxylate ReductasesReceptors, AndrogenTRPV3 protein, humanTRPV Cation Channels

Identifiers

PMID17553165
PMCPMC1904239
OpenAlexW2154384392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.